KKR Income Opportunities Fund
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KIO research report →
Price Chart
About the company
KKR Income Opportunities Fund is a close ended fixed income mutual fund launched by Kohlberg Kravis Roberts & Co. L. P.
- CEO
- Justin Takao
- IPO
- 2013
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on KIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $448.38M
- P/E
- 11.26
- PEG
- 0.09
- P/S
- 5.97
- P/B
- 0.91
- EV/EBITDA
- 13.02
- Div Yield
- 13.33%
- Gross Margin
- 87.29%
- Op Margin
- 65.89%
- Net Margin
- 53.16%
- ROE
- 7.87%
- ROIC
- 6.75%
Latest fiscal year · YoY change
- Revenue
- $35.21M-48.8%
- Gross Profit
- $49.82M-27.5%
- Op Income
- $32.26M
- Net Income
- $23.29M-64.7%
- EPS
- $0.57-76.5%
- OCF Growth
- -52.5%
- FCF Growth
- -52.5%
- 52W High
- $12.76
- 52W Low
- $10.65
- 50D MA
- $11.17
- 200D MA
- $11.36
- Beta
- 0.56
- RSI (14)
- 38
- Avg Volume
- 185.41K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
KIO’s Q3 update showed flat-to-slightly-negative NAV performance, with management saying the portfolio is positioned for an inflationary, rising-rate backdrop by leaning more into loans and higher-collateral credits.· November 10, 2021
- Q3 NAV performance was slightly negative at down 35 bps; year-to-date NAV was up 4.91%.
- Management said the market backdrop improved as Delta-related worries faded and leisure/travel names recovered, including cruise-related credits.
- The team is favoring floating-rate loans over high yield bonds because loan spreads/yields remain more attractive and the portfolio is underweight duration.
- They see opportunities from supply-chain and labor dislocations, where bonds can trade off 3 to 5 points on earnings/margin misses.
- Credit conditions were described as healthy, with default rates below 1% and recoveries improving versus 2020.
KIO’s NAV was down 35 basis points in Q3 and up 4.91% year to date. In the broader market, Aaron Dalrymple said Q3 U.S. high yield bonds were up 94 basis points and loans were up a little over 1%; year to date, high yield was up 4.7% and loans were up just under 4.5%. Management did not provide revenue, EPS, gross margin, or per-share fund distribution figures on this call. Looking ahead, they expect to stay underweight duration and continue leaning into loans, which they believe are better positioned for inflation and potential rate hikes; they also said default rates are tracking below 1% and are expected to remain under 1% in 2022.
There was no CEO on the call, but the lead commentary from Jeremiah Lane and Aaron Dalrymple was constructive and opportunistic. They said many Q3 COVID-related concerns were already in the rearview mirror, and that leisure, cruise, travel, and other recovery trades were improving into Q4. Strategically, they emphasized KIO’s flexible mandate, ability to pivot across loans and bonds, and focus on sourcing dislocated credits with pricing power and strong collateral.
There was no CFO on the call and no fund-level financial statements were presented. The closest financial framing came from Aaron Dalrymple, who said KIO’s NAV was down 35 bps in Q3 and up 4.91% year to date, while the broader loan and high-yield markets posted positive returns in the quarter. He also noted the portfolio continues to generate an attractive yield and that the team is pivoting more toward floating-rate loans as rates and inflation move higher.
In the discussion around Q&A-style topics, management was asked about structural inefficiencies in loans and how KIO can take advantage of them. Jeremiah Lane pointed to CLO constraints, rating-driven forced selling, and the ability to buy dislocated loans and bonds when credits are temporarily downgraded despite underlying recovery. They also addressed macro concerns such as inflation, supply-chain disruption, labor costs, and Fed tightening, saying the portfolio is underweight duration and positioned for one to two rate hikes next year, with continued monitoring of sectors like leisure, hospitals, and building products.
The bull case from this call is that the portfolio is positioned for the current macro setup: underweight duration, more exposed to floating-rate loans, and focused on credits with pricing power and strong collateral. Management also sounded encouraged by improving leisure/travel fundamentals, healthy flow support for loans, and a credit backdrop with low defaults and improving recoveries.
The main risks discussed were inflation, supply-chain disruption, and labor-cost pressure, which can cause temporary margin compression and even 3 to 5 point selloffs in bonds when companies miss earnings. Management also flagged continued caution around commodity-linked sectors and underweights in energy, reflecting concern about cash-flow volatility and weaker visibility.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 40.99M
- Float Shares
- 40.99M
of shares held by institutions
94 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 3.00M | ▲ 251.32K |
| Penserra Capital Management LLC | 1.16M | ▲ 44.34K |
| Guggenheim Capital LLC | 851.50K | ▲ 57.94K |
| Ubs Group AG | 646.65K | ▼ 13.81K |
| Wells Fargo & Company/Mn | 548.46K | ▼ 34.69K |
| Janney Montgomery Scott LLC | 536.53K | ▲ 66.76K |
| Bank Of America Corp | 348.01K | ▲ 6.09K |
| Lpl Financial LLC | 217.25K | ▲ 4.30K |
| Kovack Advisors, Inc. | 216.68K | ▲ 81.65K |
| Rareview Capital LLC | 198.86K | ▲ 18.25K |
| Shaker Financial Services, LLC | 175.57K | ▼ 140.06K |
| Karpus Management, Inc. | 162.93K | ▼ 5.76K |
Held by 20 ETFs
Biggest fund positions in KIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 8, 26 | O'Donnell-Butner Annette | other | 0 |
| Feb 3, 26 | Takao Justin | sell | 7,310.151 |
| Feb 3, 26 | Takao Justin | sell | 7,397 |
| Feb 3, 26 | Takao Justin | sell | 100 |
| Feb 4, 26 | Takao Justin | sell | 1,415.98 |
| Feb 4, 26 | Takao Justin | sell | 4,994 |
| Nov 1, 25 | Takao Justin | other | 0 |
| Dec 31, 24 | Levy Tobin V | other | 0 |
| Nov 1, 24 | Perez-Berkeley Lourdes | other | 0 |
| Jan 1, 24 | Pimentel Rudy | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KIO coverage
Recent articles, reports, and earnings notes.
No research on KIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KIO report →Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
newsfilecorp.com · Aug 19
KKR Income Opportunities Fund (NYSE:KIO) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened
defenseworld.net · Aug 14
KIO: Income May Increase Going Forward, But The Distribution Is Destroying NAV
seekingalpha.com · Jul 2
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
newsfilecorp.com · Jun 18
KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share
businesswire.com · Jun 8
KIO: High Beta Fixed Income CEF With Significant Downside (Rating Downgrade)
seekingalpha.com · Apr 17
KKR Income Opportunities Fund (NYSE:KIO) Stock Crosses Above 50-Day Moving Average – Here’s What Happened
defenseworld.net · Apr 17
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
newsfilecorp.com · Apr 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.